GZMB and dermatitis: GzmB−/− mice exhibited fewer mast cells, less severe dermatitis, and better skin barrier function compared with wild controls in an oxazolone (OXA)-induced mouse dermatitis model (OXA was repeatedly applied as a hapten to the mouse ear to cause skin inflammation similar to that of human AD), indicating that GzmB may be a potential therapeutic target for AD (107).